US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Dermatitis, Atopic · Cancer
Janssen-Cilag Pty
Janssen-Cilag Pty Ltd
Janssen-Cilag Pty drug portfolio — 24 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
SYDNEY, IT HQ
118 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- SYDNEY, IT
- Employees
- 118
- Programs
- 3
- Drugs
- 24
- Patents
- 0
Janssen-Cilag Pty pipeline
Portfolio lens on 24 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Janssen-Cilag Pty drug portfolio — 24 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
amivantamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Janssen-Cilag Pty's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor inhibitor
-
apalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
darunavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 protease.
- Target
- Human immunodeficiency virus type 1 protease
- Mechanism
- Human immunodeficiency virus type 1 protease inhibitor
-
Development asset linked to Janssen-Cilag Pty in public FDA and regional records.
-
Development asset linked to Janssen-Cilag Pty in public FDA and regional records.
-
Development asset linked to Janssen-Cilag Pty in public FDA and regional records.
-
Development asset linked to Janssen-Cilag Pty in public FDA and regional records. Mechanism: Prostanoid IP receptor agonist.
- Mechanism
- Prostanoid IP receptor agonist
-
esketamine
Nervous system (N06)Nervous system (N06) compound in Janssen-Cilag Pty's portfolio. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
etravirine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
golimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
guselkumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-23.
- Target
- Interleukin-23
- Mechanism
- Interleukin-23 inhibitor
-
ibrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
Development asset linked to Janssen-Cilag Pty in public FDA and regional records.
-
macitentan
Cardiovascular system (C02)US regulatory status: approved. Molecular target: Endothelin receptor, ET-A/ET-B.
- Target
- Endothelin receptor, ET-A/ET-B
- Mechanism
- Endothelin receptor, ET-A/ET-B antagonist
-
Development asset linked to Janssen-Cilag Pty in public FDA and regional records.
-
paliperidone
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
rilpivirine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
selexipag
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Prostacyclin receptor.
- Target
- Prostacyclin receptor
- Mechanism
- Prostanoid IP receptor agonist
-
Development asset linked to Janssen-Cilag Pty in public FDA and regional records.
-
tacrolimus
Dermatologicals (D11)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
Development asset linked to Janssen-Cilag Pty in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
ustekinumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-12.
- Target
- Interleukin-12
- Mechanism
- Interleukin-23 inhibitor